Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-target CART-19 and 20 in R/R NHL
NCT06160362Phase 1Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR-T cells in non-Hodgkin lymphoma (NHL), sponsored by Henan Cancer Hospital. Primary endpoint: Safety as assessed by the occurrence of study related adverse events at 1 month. Started Oct 2023; status: recruiting.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06160362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06160362.